Azora Therapeutics, Inc. (DE) AZR
NASDAQ AZR
$4.09 +0.35 (+9.36%)
At close: Nov 13, 2026 · 4:00 PM EST

Azora Therapeutics, Inc. (DE) (AZR) Non Operating Interest Expenses (2017 - 2023)

Updated

Azora Therapeutics, Inc. (DE) (AZR) reported Non Operating Interest Expenses of $14,000 for Q1 2023.

Analysis

Azora Therapeutics, Inc. (DE) (AZR) Non Operating Interest Expenses (2017 - 2023) Analysis & Trends

Over the twelve months ended Mar 31, 2023, Azora Therapeutics, Inc. (DE)'s Non Operating Interest Expenses came in at $51.02 million; for FY2018, it was $24,431, down 76.0% from FY2017.

  • By year, Non Operating Interest Expenses came in at $101,637 in FY2017.
  • The Q1 2023 figure ranks as the highest quarterly Non Operating Interest Expenses since Q1 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 217.00 Mn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn -
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn -
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 269.00 Mn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn -
10 Azora Therapeutics, Inc. (DE) 58.43 Mn -2.79 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 14,000.00
Mar 31, 2019 51.00 Mn
Sep 30, 2018 1,068.00
Jun 30, 2018 50,889.00
Mar 31, 2018 23,363.00
Dec 31, 2017 163,976.00
Sep 30, 2017 -30,210.00
Jun 30, 2017 22,826.00
API Access

Azora Therapeutics, Inc. (DE) Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=AZR&period=max&api_key=YOUR_API_KEY